Article

Towards automated manufacturing of clinical scale gene-modified T cells

2014-01-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 850179ab-c536-5166-ac0d-06a89ea56bcb
DOI: 10.1186/2051-1426-2-s3-p21
PMCID: PMC4288587

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Towards automated manufacturing of clinical scale gene-modified T cellsDOI 10.1186/2051-1426-2-s3-p21Read

Manufacturing genetically modified T cells for clinical trialsSemantic proximity Read

Toward precision manufacturing of immunogene T-cell therapiesSemantic proximity Read

Towards a commercial process for the manufacture of genetically modified T cells for therapySemantic proximity Read

Revolutionizing CAR T Cell Therapies: Innovations in Genetic Engineering and Manufacturing to Enhance Efficacy and AccessibilitySemantic proximity Read

Automated, scaled, transposon-based production of CAR T cellsSemantic proximity Read

Scaling up and scaling out: Advances and challenges in manufacturing engineered T cell therapiesSemantic proximity Read

Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trialSemantic proximity Read

GMP manufacturing of cell and gene therapy products: Challenges, opportunities, and pathways forwardSemantic proximity Read

Streamlined production of genetically modified T cells with activation, transduction and expansion in closed-system G-Rex bioreactorsSemantic proximity Read

Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell ImmunotherapiesSemantic proximity Read

Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapySemantic proximity Read

A simple and robust clinical manufacturing process for the ex-vivo expansion of autologous T cells genetically engineered to express an anti-BCMA chimeric antigen receptor (CAR) for the treatment of multiple myelomaSemantic proximity Read